Clinical experience of integrative cancer immunotherapy with GcMAF

Anticancer Research

Volumn 33, Issue 7, 2013, Pages 2917-2920

  Inui, Toshio ^a,b,c,d   Kuchiike, Daisuke ^a,b   Kubo, Kentaro ^b   Mette, Martin ^d   Uto, Yoshihiro ^a   Hori, Hitoshi ^a   Sakamoto, Norihiro ^e  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b Saisei Mirai Clinic   (Japan)

^c SAISEI MIRAI Clinic Kobe   (Japan)

^d Inui Clinic   (Japan)

^e KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Alpha lipoic acid; GcMAF; High dose vitamin C; Hyper T NK cells; Immunotherapy

Indexed keywords

ASCORBIC ACID; COLECALCIFEROL; GROUP SPECIFIC COMPONENT MACROPHAGE ACTIVATING FACTOR; MACROPHAGE ACTIVATING FACTOR; THIOCTIC ACID; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ADVANCED CANCER; AGED; BREAST METASTASIS; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER THERAPY; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DRUG MEGADOSE; FEMALE; HUMAN; HYPERTHERMIC THERAPY; IMMUNE STATUS; LIVER CANCER; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OVARIECTOMY; PHOTODYNAMIC THERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; SERUM; SIGMOIDECTOMY; THYMUS CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME;

ALPHA LIPOIC ACID; GCMAF; HIGH-DOSE VITAMIN C; HYPER T/NK CELLS; IMMUNOTHERAPY;

AGED; ASCORBIC ACID; BONE NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; LIVER NEOPLASMS; LUNG NEOPLASMS; MACROPHAGE-ACTIVATING FACTORS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; THIOCTIC ACID; THYMUS NEOPLASMS; TISSUE THERAPY; VITAMIN D-BINDING PROTEIN;

EID: 84882721482     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Mellman I, Coukos G and Dranoff G: Cancer immunotherapy comes of age. Nature 480: 480-489, 2011.
2. Yamamoto N and Homma S: Vitamin D3-binding protein (groupspecific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci USA 88: 8539-8543, 1991.
3. Yamamoto N and Kumashiro R: Conversion of vitamin D3- binding protein (group-specific component) to a macrophageactivating factor by the stepwise action of beta-galactosidase of B-cells and sialidase of T-cells. J Immunol 151: 2794-2802, 1993.
4. Yamamoto N, Lindsay DD, Naraparaju VR, Ireland RA and Popoff SN: A defect in the inflammation-primed macrophage-activation cascade in osteopetrotic rats. J Immunol 15: 5100-5107, 1994.
5. Kisker O, Onizuka S, Becker CM, Fannon M, Flynn E, D'Amato R, Zetter B, Folkman J, Ray R, Swamy N and Pirie-Shepherd S: Vitamin D-binding protein-macrophage-activating factor (DBPmaf) inhibits angiogenesis and tumor growth in mice. Neoplasia 5: 32-40, 2003.
6. Pacini S, Punzi T, Morucci G, Gulisano M and Ruggiero M: Effects of vitamin D-binding protein-derived macrophage-activating factor on human breast cancer cells. Anticancer Res 32: 45-52, 2012.
7. Yamamoto N, Suyama H, Yamamoto N and Ushijima N: Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage-activating factor (GcMAF). Int J Cancer 122: 461-467, 2008.
8. Yamamoto N, Suyama H and Yamamoto N: Immunotherapy for prostate cancer with Gc protein-derived macrophage-activating factor, GcMAF. Transl Oncol 1: 65-72, 2008.
9. Yamamoto N, Suyama H, Nakazato H, Yamamoto N and Koga Y: Immunotherapy of metastatic colorectal cancer with vitamin Dbinding protein-derived macrophage-activating factor, GcMAF. Cancer Immunol Immunother 57: 1007-1016, 2008.
10. Rosenberg SA, Spiess P and Lafreniere R: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318-1321, 1986.
11. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG and White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889-897, 1987.
12. Sekine T, Shiraiwa H and Yamazaki T: A feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy of cancer patients. Biomed Pharamocother 47: 73-78, 1993.
13. Utsuyama M, Hirokawa K, Kurashima C, Fukayama M, Inamatsu T, Suzuki K, Hashimoto W and Sato K: Differential age-change in the numbers of CD4+CD45RA+ and CD4+CD29+ T-cell subsets in human peripheral blood. Mech Ageing Dev 63: 57-68, 1992.
14. Ljunggren HG and Malmberg KJ: Prospects for the use of NK cells in immunotherapy of human cancer. Immunology 7: 329-339, 2007.
15. Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ and Levine M: Intravenously administered vitamin C as cancer therapy: Three cases. CMAJ 174: 937-942, 2006.
16. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E and Levine M: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a prodrug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 102: 13604-13609, 2005.
17. Packer L, Witt EH and Tritschler HJ: α-Lipoic acid as a biological antioxidant. Free Rad Biol Med 19: 227-250, 1995.
18. Casciari JJ, Riordan NH, Schmidt TL, Meng XL, Jackson JA and Riordan HD: Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours. Br J Cancer 84: 1544-1550, 2001.